CD30

Tumor necrosis factor receptor superfamily, member 8
Available structures
PDB	Ortholog search: PDBe, RCSB
List of PDB id codes
	1D01
Identifiers
Symbols	TNFRSF8; CD30; D1S166E; Ki-1
External IDs	OMIM: 153243 MGI: 99908 HomoloGene: 949 GeneCards: TNFRSF8 Gene
Gene Ontology
Molecular function	• transmembrane signaling receptor activity; • tumor necrosis factor-activated receptor activity;
Cellular component	• cytoplasm; • plasma membrane; • integral to membrane;
Biological process	• signal transduction; • negative regulation of cell proliferation; • tumor necrosis factor-mediated signaling pathway; • positive regulation of tumor necrosis factor biosynthetic process; • positive regulation of apoptotic process; • positive regulation of TRAIL biosynthetic process; • cellular response to mechanical stimulus;
	Sources: Amigo / QuickGO
RNA expression pattern
	More reference expression data
Orthologs
	This box: view; talk; edit;

CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker.

This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.^[1]

CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors.^[2] CD30 and CD15 are also expressed on classical Hodgkin Lymphoma Reed-Sternberg cells.^[3]

Interactions[edit]

CD30 has been shown to interact with TRAF5,^[4] TRAF1,^[5] TRAF2^[4]^[5] and TRAF3.^[5]

Cancer Treatment[edit]

CD30 is the target of the FDA approved therapeutic Brentuximab Vedotin (Adcetris), designed and developed by Seattle Genetics. It is approved for use in:
1) Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT)
2) HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
3) Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen ^[6]

References[edit]

^ "Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily, member 8".
^ Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi (in Chinese) 34 (11): 711–5. PMID 16536313.
^ Gorczyca W, Tsang P, Liu Z, et al. (February 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". Int. J. Oncol. 22 (2): 319–24. PMID 12527929.
^ ^a ^b Aizawa, S; Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T (January 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". J. Biol. Chem. 272 (4): 2042–5. doi:10.1074/jbc.272.4.2042. PMID 8999898.
^ ^a ^b ^c Ansieau, S; Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, Harada J, Dougall B, Hübinger G, Kieff E, Herrmann F, Leutz A, Gruss H J (November 1996). "Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation". Proc. Natl. Acad. Sci. U.S.A. 93 (24): 14053–8. doi:10.1073/pnas.93.24.14053. PMC 19493. PMID 8943059. (Retracted. If this is intentional, please replace {{Retracted}} with {{Retracted|intentional=yes}}.)
^ Changchun, Deng; Beiqun Pan, Owen A. O'Connor (15). "Brentuximab Vedotin". Clinical Cancer Research 19: 22. PMID 23155186.

Further reading[edit]

Schneider C, Hübinger G (2003). "Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family". Leuk. Lymphoma 43 (7): 1355–66. doi:10.1080/10428190290033288. PMID 12389614.
Horie R, Higashihara M, Watanabe T (2003). "Hodgkin's lymphoma and CD30 signal transduction". Int. J. Hematol. 77 (1): 37–47. doi:10.1007/BF02982601. PMID 12568298.
Tarkowski M (2004). "Expression and a role of CD30 in regulation of T-cell activity". Curr. Opin. Hematol. 10 (4): 267–71. doi:10.1097/00062752-200307000-00003. PMID 12799531.
Granados S, Hwang ST (2004). "Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases". J. Invest. Dermatol. 122 (6): 1345–7. doi:10.1111/j.0022-202X.2004.22616.x. PMID 15175022.
Dürkop H, Latza U, Hummel M, et al. (1992). "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease". Cell 68 (3): 421–7. doi:10.1016/0092-8674(92)90180-K. PMID 1310894.
Fonatsch C, Latza U, Dürkop H, et al. (1992). "Assignment of the human CD30 (Ki-1) gene to 1p36". Genomics 14 (3): 825–6. doi:10.1016/S0888-7543(05)80203-4. PMID 1330892.
Josimovic-Alasevic O, Dürkop H, Schwarting R, et al. (1989). "Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay". Eur. J. Immunol. 19 (1): 157–62. doi:10.1002/eji.1830190125. PMID 2537734.
Stein H, Gerdes J, Schwab U, et al. (1983). "Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population". Int. J. Cancer 30 (4): 445–59. doi:10.1002/ijc.2910300411. PMID 6754630.
Jung W, Krueger S, Renner C, et al. (1995). "Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources". Mol. Immunol. 31 (17): 1329–34. doi:10.1016/0161-5890(94)90051-5. PMID 7527901.
Shiota M, Fujimoto J, Semba T, et al. (1994). "Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3". Oncogene 9 (6): 1567–74. PMID 8183550.
Lee SY, Park CG, Choi Y (1996). "T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors". J. Exp. Med. 183 (2): 669–74. doi:10.1084/jem.183.2.669. PMC 2192463. PMID 8627180.
Gedrich RW, Gilfillan MC, Duckett CS, et al. (1996). "CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins". J. Biol. Chem. 271 (22): 12852–8. doi:10.1074/jbc.271.22.12852. PMID 8662842.
Horie R, Ito K, Tatewaki M, et al. (1996). "A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages". Blood 88 (7): 2422–32. PMID 8839832.
Aizawa S, Nakano H, Ishida T, et al. (1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". J. Biol. Chem. 272 (4): 2042–5. doi:10.1074/jbc.272.4.2042. PMID 8999898.
Lee SY, Lee SY, Choi Y (1997). "TRAF-interacting Protein (TRIP): A Novel Component of the Tumor Necrosis Factor Receptor (TNFR)- and CD30-TRAF Signaling Complexes That Inhibits TRAF2-mediated NF-κB Activation". J. Exp. Med. 185 (7): 1275–85. doi:10.1084/jem.185.7.1275. PMC 2196258. PMID 9104814.
Boucher LM, Marengère LE, Lu Y, et al. (1997). "Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily". Biochem. Biophys. Res. Commun. 233 (3): 592–600. doi:10.1006/bbrc.1997.6509. PMID 9168896.
Duckett CS, Thompson CB (1997). "CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival". Genes Dev. 11 (21): 2810–21. doi:10.1101/gad.11.21.2810. PMC 316646. PMID 9353251.
Mizushima S, Fujita M, Ishida T, et al. (1998). "Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5)". Gene 207 (2): 135–40. doi:10.1016/S0378-1119(97)00616-1. PMID 9511754.
Kurts C, Carbone FR, Krummel MF, et al. (1999). "Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells". Nature 398 (6725): 341–4. doi:10.1038/18692. PMID 10192335.

External links[edit]

CD30 Antigens at the US National Library of Medicine Medical Subject Headings (MeSH)

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This membrane protein–related article is a stub. You can help Wikipedia by expanding it.

[entrez-1] "Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily, member 8".

[2] Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi (in Chinese) 34 (11): 711–5. PMID 16536313.

[3] Gorczyca W, Tsang P, Liu Z, et al. (February 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". Int. J. Oncol. 22 (2): 319–24. PMID 12527929.

[pmid8999898-4] Aizawa, S; Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T (January 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". J. Biol. Chem. 272 (4): 2042–5. doi:10.1074/jbc.272.4.2042. PMID 8999898.

[pmid8943059-5] Ansieau, S; Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, Harada J, Dougall B, Hübinger G, Kieff E, Herrmann F, Leutz A, Gruss H J (November 1996). "Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation". Proc. Natl. Acad. Sci. U.S.A. 93 (24): 14053–8. doi:10.1073/pnas.93.24.14053. PMC 19493. PMID 8943059. (Retracted. If this is intentional, please replace {{Retracted}} with {{Retracted|intentional=yes}}.)

[6] Changchun, Deng; Beiqun Pan, Owen A. O'Connor (15). "Brentuximab Vedotin". Clinical Cancer Research 19: 22. PMID 23155186.

[1]

[2]

[3]

[4]

[5]

[6]

CD30

Contents

Interactions[edit]

Cancer Treatment[edit]

References[edit]

Further reading[edit]

External links[edit]

Navigation menu

Personal tools

Namespaces

Variants

Views

Actions

Search

Navigation

Interaction

Toolbox

Print/export

Languages